Why the study?
The role of chronic, low-grade inflammation in cardiovascular disease and its clinical implications require updated understanding and consensus recommendations.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Despite advances such as interleukin‑6–targeted therapies, implementation remains limited, as clinicians are unlikely to treat what they do not routinely measure. Addressing current gaps in inflammatory risk assessment presents both a challenge and an opportunity to better personalize CVD prevent...”
This 2025 ACC Scientific Statement establishes that the evidence linking inflammation with atherosclerotic CVD is compelling and clinically actionable, providing consensus recommendations for screening and treatment.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Mensah et al. (2025) conducted a review in Cardiovascular disease. Anti-inflammatory therapies and inflammation screening was evaluated. Chronic, low-grade inflammation is a compelling and clinically actionable risk factor for cardiovascular disease, with hsCRP serving as a strong predictor of recurrent events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: